This profile has not been claimed and data may not be accurate.
Founder363Past founder
98th percentile
Investor27Current investor
70th percentile
Combined
Moderna co-founder and mRNA pioneer with h-index 129
• Industries:Biotech
Credibility
this founder typical founder (50th pct)
Domain Expertise · 99th percentile
- Deep research credibility: h-index 129 and 57,312 citations across 407 works (OpenAlex).
- Recipient of the Pasarow Foundation Award and Walter B. Cannon Award, with honorary doctorate from the University of Edinburgh — recognized for domain expertise in cardiovascular science.
- Wikipedia entity exists for Kenneth R. Chien, confirming notable public figure status.
- Identified researcher on OpenAlex with 407 published works and 57,312 citations.
Relationship Matrix
Founder score
- 97%Probability of being accurate (97%)Deep research credibility: h-index 129 and 57,312 citations across 407 works (OpenAlex).
- 97%Probability of being accurate (97%)Current Co-Founder of Moderna, still holding an active co-founder role since January 2010.
- 97%Probability of being accurate (97%)Wikipedia entity exists for Kenneth R. Chien, confirming notable public figure status.
- 97%Probability of being accurate (97%)Identified researcher on OpenAlex with 407 published works and 57,312 citations.
- 95%Probability of being accurate (95%)modernatx.com ranks #8,293 on the Majestic Million (global domain prominence).
- 95%Probability of being accurate (95%)7,768 LinkedIn followers — broad professional reach.
- 95%Probability of being accurate (95%)Google Knowledge Graph maintains a panel for Kenneth R. Chien as a recognized doctor and medical scientist.
- 92%Probability of being accurate (92%)Past founder of Celladon Corp (founded 2000) and co-founded multiple biotech ventures.
- 90%Probability of being accurate (90%)Moderna (co-founded 2010) is publicly traded with a current market cap of approximately $37.9B.
- 90%Probability of being accurate (90%)Founded the company behind modernatx/seqlike, a flagship open-source project with 208 stars on GitHub.
- 90%Probability of being accurate (90%)Moderna was co-founded with multiple co-founders, confirming a co-founding team.
- 88%Probability of being accurate (88%)Recipient of the Pasarow Foundation Award and Walter B. Cannon Award, with honorary doctorate from the University of Edinburgh — recognized for domain expertise in cardiovascular science.
- 72%Probability of being accurate (72%)Celladon Corp (co-founded 2000) went public via IPO with an estimated market cap of approximately $207M at IPO; the company was subsequently delisted.
Investor score
- 90%Probability of being accurate (90%)Publicly identified as an angel investor on Crunchbase with confirmed individual investment activity.
- 88%Probability of being accurate (88%)Made 2 tracked investments including a Series B in eTheRNA immunotherapies.
- 65%Probability of being accurate (65%)Approximately 10 years of investing experience, with earliest tracked investment activity dating to around 2010.
What you likely need
As a co-founder of Moderna and a world-renowned cardiovascular scientist, you sit at the rare intersection of deep academic research and transformative biotech company-building. You would benefit most from high-signal gatherings that connect you with other founder-scientists navigating the academic-to-commercial translation challenge, as well as investors and operators in the life sciences and mRNA therapeutics space. Events focused on biotech founder networks, mRNA platform commercialization, and cardiovascular medicine innovation would be especially valuable.
Would you attend these IRL Festival events?
We will tune and customize your Founder Festival experience to make sure you get invited to the events that would be most valuable to you.
- introsA biotech founder dinner with other scientist-founders who have taken academic discoveries to public company scale, to share lessons on the academic-to-commercial transition.
- positioningA roundtable on next-generation mRNA therapeutics platforms with founders and CSOs building in the post-COVID mRNA infrastructure wave.
- fundraisingAn office-hours session with top life sciences VCs (a16z Bio, Flagship Pioneering) to explore advisory or co-founding opportunities in cardiovascular regenerative medicine.
- tacticalA cardiovascular medicine founder network dinner connecting academic PIs who have spun out companies, focused on IP strategy and clinical translation.
- introsAn EQT life sciences portfolio dinner to deepen relationships with European biotech operators and identify advisory or board opportunities.
- hiringA Moderna co-founder and early team alumni happy hour to reconnect with the mRNA platform's founding generation and explore new ventures.
- wellbeingA curated dinner for researcher-founders with h-index 100+ who have commercialized their science, to discuss the unique challenges of scientist-led company building.